SK Biopharmaceuticals (KRX:326030) signed a pharmaceutical supply contract worth 99.4 billion won with its US subsidiary, SK Life Science, according to a Tuesday filing with the Korean Exchange.
The contract is to supply its epilepsy treatment cenobamate, which is sold in the US market under the brand name, XCOPRI.